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ABSTRACT 
Mucinous variant of intrahepatic cholangiocarcinoma (iCC) is rare, and its 
clinicopathological features and prognosis are far less clear. Six patients who had iCCs 
with more than 50% of mucinous component and 79 conventional iCCs were included in 
the study. The mean size of mucinous and conventional iCCs was 6.2 cm and 6.0 cm, 
respectively. The majority of patients (83%) with mucinous iCC presented at T3 stage or 
above, compared to 28% of the conventional group (p < 0.01). Three patients with 
mucinous iCC (50%) died within 1 year. The average survival time of patients with 
mucinous iCCs was significantly reduced compared to that of conventional group (9 
months vs 2 years; p < 0.001). Immunohistochemistry was performed on 6 mucinous 
and 12 conventional iCCs with matched age, sex and stage, which revealed positive 
immunoreactivity in MUC1 (83% vs 58%), MUC2 (33% vs 17%), MUC5AC (100% vs 
42%), MUC6 (50% vs 0), CK7 (83% vs 83%), CK20 (0 vs 17%), and CDX2 (17% vs 0) 
in mucinous and conventional iCCs, respectively. Molecular studies showed one 
mucinous iCC with KRAS G12C mutation and no BRAF or IDH1/2 mutations. Mucinous 
iCC is a unique variant that constitutes 7.2% of iCCs. It is more immunoreactive for 
MUC1, MUC2, MUC5AC and MUC6. Unlike adenocarcinomas of colorectal primary, 
mucinous iCCs are often CK7+/CK20-/CDX2- and microsatellite stable. Patients with 
mucinous iCC likely present at advanced stage upon diagnosis with shorter survival 
time compared to the conventional counterparts. 
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INTRODUCTION 
Cholangiocarcinoma is a malignancy with biliary epithelium differentiation that 
has drawn attention recently due to its increased incidence and poor prognosis [1,2]. 
Clinically, cholangiocarcinoma is classified as intrahepatic, perihilar, and distal types 
based on its anatomic location [3].  
Intrahepatic cholangiocarcinoma (iCC) accounts for 10-20% of all primary liver 
malignancy [2,3], which arises from small branches of biliary tree within the 
parenchyma. Multiple schemes have been attempted for further classification [4]. Based 
on morphological features, the Liver Cancer Study Group of Japan established the 
macroscopic classification: mass-forming, periductal-infiltrating, and intraductal growth 
[5]. Mass-forming type constitutes discrete mass; periductal-infiltration type extends 
longitudinally along the bile duct, often resulting in dilatation of the peripheral bile duct; 
intraductal growth type proliferates within the lumen of the bile duct. In 2014, Liau and 
colleagues sub-classified 189 iCCs into bile duct and cholangiolar subtypes based on 
histomorphological features [6]. Cholangiolar type is composed of cuboidal to low 
columnar cells with scanty cytoplasm. The bile duct subtype is composed of tall 
columnar cells arranged in glandular pattern. Recently, Hayashi et al investigated 102 
consecutive iCCs and sub-classified into type 1 and type 2 based on the combined 
features of extracellular mucin production and immunophenotype [7].     
 By convention, mucinous carcinoma is defined when extracellular mucinous 
components occupy at least 50% of total tumor volume [8,9]. It is known that patients 
with mucinous carcinoma arising in the breast, pancreas, colon and gallbladder have a 
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different survival rate compared to their conventional counterparts [10-12] [9,13,14]. So 
far, there have been no studies performed in the United States of America regarding the 
incidence, prognosis, and morphological features of mucinous iCCs. In this study, we 
retrospectively analyzed 85 consecutive iCCs, and aimed to investigate the 
clinicopathological features and prognosis of mucinous iCCs. 
 
MATERIALS AND METHODS 
Patients 
Computerized search in the pathology database from Indiana University Health 
was performed over a period of 9 years from 2007 to 2016 to identify all liver resections 
with a diagnosis of iCC. A total of 85 cases were found. Among them, 6 cases were 
classified as mucinous iCC in which the extracellular mucin consisted of at least 50% of 
tumor volume. All cases in the study were grossly examined according to the 
standardized protocol in which at least one tumor section was taken for histologic 
examination per 1 cm of tumor mass. One to three random sections were also taken in 
the non-neoplastic background liver parenchyma. Clinical information regarding 
patients’ age, gender, liver disease and prognosis was retrieved. The study was 
approved by the Institutional Review Board.  
 
Histomorphologic review  
All specimens were partial hepatectomies and the hematoxylin and eosin-stained 
(H&E) slides were reviewed by two pathologists (ZC and JL). The pathologic diagnosis 
of iCC was confirmed in all cases according to the World Health Organization 
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Classification guidelines[15]. Tumor differentiation, location, size, number, surgical 
margin status, percentages of mucin component, epithelial type, tumor necrosis, 
presence of signet-ring cells, perineural invasion, and lymphovascular invasion were 
evaluated.  
 
Immunohistochemical evaluation 
Immunohistochemistry was performed in 6 mucinous and 12 conventional iCCs 
with matched age, sex and tumor stage. A representative tumor section was used in 
each case. Briefly deparaffinized tissue sections were stained with antibodies against 
MUC1, MUC2, MUC5AC, MUC6, CK7, CK20, PMS2, MSH6, p53, Smad 4, EGFR, Her2 
and CDX2. Immunohistochemical staining was carried out with a mouse monoclonal 
anti-MUC1 (provided working solution; Leica, Bannockburn, IL), MUC2 (provided 
working solution; Leica, Bannockburn, IL), MUC5AC (provided working solution; Leica, 
Bannockburn, IL), MUC6 (provided working solution; Leica, Bannockburn, IL), CK7 
(provided working solution; Dako, Carpinteria, CA), CK20 (provided working solution; 
Dako, Carpinteria, CA), PMS2 (provided working solution, BD Biosciences, CA), MSH6 
(provided working solution, Zymed, San Fransisco, CA), p53 (provided working solution, 
ONCOGENE SCIENCE, Cambridge, MA), Smad 4 (provided working solution; Santa 
Cruz, Dallas, TX), EGFR (provided working solution; Abcam, Cambridge, MA), Her 2 
(provided working solution; Dako, Carpinteria, CA),  and CDX2 (provided working 
solution, Biogenex, San Ramon, CA). A high pH buffer solution in a “PT module” was 
used for antigen retrieval followed by incubation times of 10 minutes each with primary 
antibody, Envision FLEX+M linker, Envision FLEX/horseradish peroxidase (Dako, 
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Carpinteria CA), and diaminobenzidine. Representative fields were selected at a 
magnification of ×200 using an Olympus BX51 microscope. If greater than 10% of the 
tumor cells showed cytoplasmic staining (MUC2, MUC5AC, MUC6, CK7, CK20, EGFR), 
apical membranous or cytoplasmic staining (MUC1), membranous staining (Her 2), or 
nuclear staining (p53, CDX2, PMS2, MSH6, Smad 4), the result was interpreted as 
positive. The result for MUC1, MUC2, MUC5AC and MUC6, was further scored as 0-4 
(0= none – 10% staining, 1= 10-25%, 2= 26-50%, 3= 51-75%, and 4= 76-100%).  
Molecular study for BRAF/KRAS/IDH mutations  
Extraction of DNA was performed using Qiagen QIAamp DNA Formalin-fixed 
Paraffin-embedded Tissue Kit (Qiagen, Valencia, CA, USA). DNA concentration was 
determined using NanoDrop Spectrophotometer and subsequently diluted with distilled 
water to adjust the concentration to 10 ng/ul in distilled water.  
BRAF mutation analysis was performed using Qiagen therascreen BRAF RGQ 
Kit (Qia Qiagen, Valencia, CA, USA gen), which detects five somatic mutations at codon 
600 of BRAF oncogene (V600E, V600E complex, V600D, V600K, and V600R). Qiagen 
therascreen KRAS RGQ Kit (Qiagen, Valencia, CA, USA) was used to detect seven 
somatic KRAS mutations in codons 12 and 13. IDH1/2 mutation analysis was performed 
using Qiagen IDH1/2 RGQ PCR Kit (Qiagen), which detect mutations of codon 132 and 
100 in IDH1 gene and codon 172 in IDH2 gene as well as R132C, R132H, and R172K 
mutations.  
PCR amplified products for BRAF, KRAS, and IDH1/2 were analyzed on Rotor-
Gene Q MDx instrument which uses both Scorpions and Amplification Refractory 
Mutation System technologies (Qiagen, Valencia, CA, USA). The threshold at which the 
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signal is detected above background signaling is called cycle threshold. Sample delta 
cycle threshold values are calculated as the difference between mutation assay cycle 
threshold and wild-type assay cycle threshold from the same sample. Samples are 
subsequently classified as mutation positive if they give a delta cycle threshold less than 
the stated cutoff value for the assay, or as mutation not detected if above this value. 
The data was analyzed using Rotor-Gene Q series software. Appropriate positive and 
negative controls were run with each sample. 
 
Statistics 
Categorical data were compared using χ2 test. Continuous data was compared 
using Student t test. A P value less than 0.05 is considered statistically significant. 
 
RESULTS 
Demographics  
Among 6 patients with mucinous iCC, 4 were men (66%) and the average age 
was 59 years (range, 40–82 years). Among them, one patient had pre-surgery 
neoadjuvant (gemcitabine and cisplatin) and radiation therapy.  
Thirty-four of 79 patients in conventional group were men (43%) and the average 
age was 61 years (range, 52–82 years) (Table 1). Among them, 7 (9%) and 19 (25%) 
patients had pre-surgery and post-surgery neoadjuvant and radiation therapy, 
respectively. The regimen of neoadjuvant therapy consisted mainly of gemcitabine and 
cisplatin. Some patients received 5-FU, Xeloda, Taxotere, Capecitabine, and oxaliplatin. 
There was no age or gender difference between mucinous and conventional groups (P 
> 0.05). 
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Histopathologic evaluation 
The sites of iCCs were in peripheral liver parenchyma for all cases in the study. 
The average size of tumor was 6.2 cm (range, 1.2–15 cm) in mucinous group and 6.0 
cm (range, 1.2–18 cm) in conventional group (P > 0.05) (Table 1). Grossly, all 6 
mucinous iCCs were mass-forming. 
As shown in Table 2, three patients in mucinous group (50%) had positive 
surgical margins. Necrosis was present in four cases (67%) and three showed signet 
ring cells features (50%). Perineural invasion and lymphovascular invasion were 
present in all six mucinous cases. The predominant epithelial type was bile duct (67%), 
and the other types included cholangiolar (17%), and unclassified (17%) (Figure 1). 
Non-neoplastic liver parenchyma in mucinous iCCs (Table 2) revealed diverse histologic 
changes including bridging fibrosis (1 case), cirrhosis (2 cases), steatohepatitis (1 
case), and primary sclerosis cholangitis (1 case).  
 
Immunohistochemistry  
Immunohistochemistry for MUC1, MUC2, MUC5AC, MUC6, CK7, CK20, PMS2, 
MSH6, p53, Smad 4, EGFR, Her2, and CDX2 was performed in 6 cases of mucinous 
variant and 12 cases of conventional iCCs (Figure 2; Tables 2 and 3). With matched 
age, sex and tumor stage, immunohistochemical analysis revealed positive 
immunoreactivity in MUC1 (83% vs 58%), MUC2 (33% vs 17%); MUC5AC (100% vs 
42%), MUC6 (50% vs 0), CK7 (83% vs 83%), CK20 (0 vs 17%), and CDX2 (17% vs 0) 
in mucinous variant and conventional iCCs, respectively.  
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Immunohistochemistry for PMS2 and MSH6 showed intact nuclear staining in all 
mucinous iCC cases, and 83% and 92% retained staining in conventional iCCs, 
respectively. P53 immunohistochemistry showed a 67% frequency of immunoreactivity 
in both mucinous and conventional iCCs. Smad and EGFR revealed 67% vs 58%, and 
83% vs 42% immunoreactivity in mucinous and conventional iCCs, respectively. Her 2 
immunoreactivity was negative in both groups. 
Additionally, 16 cases of liver metastases from patients with known colorectal 
adenocarcinoma were selected to compare immunoreactivity for CK7, CK20 and CDX2. 
As shown in Table 3, liver metastases from colorectal primary showed distinct 
immunoreactivity for CK7 (6% vs 83% vs 83%), CK20 (94% vs 0 vs17%), and CDX2 
(94% vs17% vs 0) compare to mucinous and conventional iCCs. 
 
Molecular study 
Molecular studies were performed in 6 mucinous iCCs. Only one case (patient 5) 
showed KRAS G12C mutation. No BRAF or IDH1/2 mutations were detected. 
 
Staging and prognosis  
The tumor staging is shown in Table 1 that was evaluated according to the 7th 
AJCC Cancer Staging Manual. No mucinous iCCs presented as T1 tumor compared to 
that of 43% in conventional group. Mucinous iCCs presented as T2 (17%), T3 (50%) 
and T4 (33%) tumors, compared to those of 27%, 19% and 11% in conventional group, 
respectively. Taken together, 83% of mucinous iCCs demonstrated as T3 and above 
stage compared to that of 30% of conventional group (P<0.01). Among the cases 
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wherein nodal dissection was performed, 40% of mucinous and 24% of conventional 
iCCs had nodal metastases (N1). Within mucinous group, one patient (17%) had tumor 
present in a celiac node which was counted as distant metastasis (M1) [16]. Due to the 
unknown status of distal metastasis and loss of clinical followup in majority of the cases, 
an objective comparison could not be performed in this regard. 
One-year survival rates were 25% in mucinous group compared to 27% in 
conventional group (Table 1). The average survival time was 9 months in mucinous 
group and 2 years in conventional group (P < 0.001).Three patients (50%) within 
mucinous groups had tumor recurrence 1, 17 and 20 months post hepatectomy. 
 
DISCUSSION 
In this retrospective study from a tertiary medical center with a large volume of 
hepatectomies, mucinous variant constitutes 7.2% of iCCs. Although it is rare, mucinous 
iCC is morphologically distinctive. Macroscopically, it often forms a mass that falls into 
the category of mass-forming type according to the classification of the Liver Cancer 
Study Group of Japan[5]. Microscopically, mixed epithelial components are appreciated 
in mucinous variants, which are composed of both bile duct (predominant) and 
cholangiolar types [6]. By definition, mucinous variant is composed of tumor cells with 
profound mucin production (≥ 50% involvement), which falls into type 1 iCC according to 
Hayashi’s classification[7]. In addition, higher frequency of perineural invasion in 
mucinous iCCs as observed in our study support this classification. 
Immunophenotypically, mucinous variant is unique. It is more immunoreactive for 
all mucinous markers including MUC1, MUC2, MUC5AC and MUC6 compared to 
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conventional iCC. Among these immunomarkers, MUC1 (mammary gland-type 
apomucin) is commonly expressed in pancreaticobiliary tumors[17]; MUC2, MUC5AC 
and MUC6 are specific for intestinal goblet cells[18], gastric foveolar cells[17], and 
gastric pyloric cells[9], respectively. Interestingly, MUC1 expression is associated with 
poor prognosis in cholangiocarcinoma[19]. General expression of mucinous markers in 
this unique variant is consistent with its intuitive nature, while the subtle heterogeneity 
may be due to discrete nature of each individual tumor itself. In addition, unlike 
mucinous adenocarcinomas of colorectal primary, mucinous iCCs are often 
CK7+/CK20-/CDX2- and microsatellite stable. Therefore, an immunohistochemical 
panel including CK7, CK20, and CDX2 is useful to differentiate metastatic colorectal 
carcinoma from mucinous iCCs in a patient who has unknown primary and the liver 
tumor shows mucinous morphology. 
Various pathways have been implicated in pathogenesis of iCCs that comprises 
accumulation of genetic mutations and epigenetic modifications. Multiple mutational 
events have been reported inclusive of EGFR, ERB2, MET, KRAS, TP53, BRAF, PTEN, 
SMAD4, IDH1, IDH2, BAP1, ARID1A, PBRMI, and NOTCH [7,16,20-26]. KRAS is a 
member of RAS family that plays an important role in regulating cell growth and 
differentiation.[27] The importance of KRAS in pathogenesis of iCCs is supported by 
previous studies[7], where KRAS mutation was significantly frequent in type 1 iCCs 
(29%). In Liau’s study[6], KRAS mutation was found in 23% of bile duct subtype and in 
only 1% of cholangiolar subtype. Robertson and colleagues[28] found 7.4% of iCCs had 
KRAS mutation that was associated with advanced tumor stage and nodal metastasis. 
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KRAS study performed in our report confirmed KRAS G12C mutation in one mucinous 
iCC. 
Mutations in cytoplasmic and peroxisomal isocitrate dehydrogenase (IDH1) gene 
and its mitochondrial counterpart IDH2 are present in leukemias, glioblastomas, and 
sarcomas[29]. Recently, IDH1/2 mutations in cholangiocarcinoma have been identified 
through genome-wide sequencing[30]. Hayashi et al [7] found that IDH mutation was 
restricted to type 2 iCCs (39.6%). Liau’s study[6] showed that cholangiolar subtype iCC 
displayed a higher frequency of IDH1/2 mutation than that of bile duct subtype. Our 
study detected no IDH1/2 mutation in mucinous variant. In summary, no additional 
distinct pathway is identified in mucinous variant.  
It is known that extracellular mucin producing carcinomas not only confer distinct 
morphology but also imply different clinical outcomes compared to the conventional 
counterparts[8,18]. Previous studies showed that patients with mucinous carcinomas in 
the breast and pancreas had a better 5-year survival rate [10-12], while patients with 
mucinous carcinomas from colorectal and gallbladder origins had worse 
prognosis[9,13,14]. In our study, the patients with mucinous iCC likely presented at 
advanced stage (T3 or above) with shorter survival time compared to the conventional 
counterparts.  
This is the first study in the western population, to the best of our knowledge, to 
investigate incidence, prognosis, immunohistopathological and molecular features of 
this rare variant of iCCs. In summary, mucinous variant is distinct that constitutes 7.2% 
of iCCs. Macroscopically, it is mass-forming. Microscopically, it is predominantly bile 
duct subtype. Immunophenotypically, mucinous variant is more immunoreactive for 
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MUC1, MUC2, MUC5AC and MUC6 compared to the conventional iCC. Unlike 
colorectal adenocarcinoma, mucinous iCCs are often CK7+/CK20-/CDX2- and 
microsatellite stable. Molecular studies revealed one mucinous iCC case with KRAS 
G12C mutation. Finally, it likely presents at advanced stage upon diagnosis with shorter 
survival time compared to the conventional iCCs. 
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Figure Legend 
Figure 1. Mucinous variant of intrahepatic cholangiocarcinoma (iCC). Low-power view 
(A) showing a neoplastic infiltrate with abundant mucin production replacing the normal 
liver parenchyma. High-power views of the neoplastic epithelia show cholangiolar type 
(B), bile duct type (C) and unclassified type (D). (A, magnification x 12.5; B–D, 
magnification x 400).  
 
Figure 2. Immunohistochemistry of mucinous variant of intrahepatic 
cholangiocarcinoma. MUC1, MUC2, MUC5AC or MUC6 immunohistochemistry was 
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performed for cases with cholangiolar type (A-D), bile duct type (E-H), and unclassified 
type (I-L), respectively. (A–L, magnification ×200). 
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Table 1. Clinicopathological comparison between mucinous and conventional 
intrahepatic cholangiocarcinoma (iCC). 
 Mucinous iCC (n=6) Conventional iCC 
(n=79) 
Age (range) 59 (40-82) 61 (52-82) 
Sex (F:M) 0.5 1.3 
Average size of tumor (cm, range) 6.2 (1.2 -15) 6.1 (1.2 – 18) 
Pre-surgery neoadjuvant and 
radiation therapy 
1 (17%) 7 (9%) 
Post-surgery neoadjuvant and 
radiation therapy 
0  19 (24%) 
T1 0  34 (43%) 
T2 1 (17%) 21 (27%) 
T3  3 (50%) 15 (19%) 
T4 2 (33%) 9 (11%) 
T3 and above 5 (83%)* 24 (30%) 
N1  40% (2/5) 24% (13/54) 
1-year survival rate 25% 27% 
Average survival time 9 months ** 2 years 
 
*, p<0.01, **, p<0.001, compared to the conventional group; *** The nodal status was 
unknown in one patients with mucinous iCC. 
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Table 2. Characteristics of 6 patients with mucinous intrahepatic cholangiocarcinoma.  
Patient  1 2 3 4 5 6 
Age 66 40 82 63 48 56 
Sex M M F M F M 
Race White White Black White White White 
Largest Tumor 
Size (cm) 10.1 2.4 5.1 1.2 15.0 3.5 
Tumor number 1 2 1 3 2 1 
Stage III IVA IVA III IVB IVA 
 
T T3 T4 T3 T3 T2b T4 
N Nx N0 N1 N0 N1 N0 
M Mx Mx Mx Mx 
M1 (celiac 
lymph node) Mx 
Surgical margins Positive Negative Positive Negative Negative Positive 
Non-tumor liver Bridging fibrosis 
Cirrhosis and 
PSC Normal Normal 
Steatohepatitis, 
periportal 
fibrosis 
Cirrhosis, 
unknown etiology 
Pre-surgery 
neoadjuvant and 
radiation therapy No No No No No 
Gemcitabine + 
Cisplatin + 
Radiation 
Post-surgery 
neoadjuvant and 
radiation therapy 
No No No No No No 
Tumor 
differentiation       
 
WD 40% 80% 40% 20% 10% 70% 
MD 60% 10% 60% 70% 60% 20% 
PD 0 10% 0 10% 30% 10% 
Mucinous 
involvement 90% 90% 70% 60% 80% 80% 
Epithelial type Cholangiolar Unclassified Bile duct Bile duct Bile duct Bile duct 
Necrosis Yes Yes No Yes Yes No 
Signet-ring cell No Yes No Yes No Yes 
Perineural 
invasion Yes Yes Yes Yes Yes Yes 
Lympho-vascular 
invasion Yes Yes Yes Yes Yes Yes 
MUC1 ++++ - + +++ ++ ++ 
MUC2 ++ - - - - + 
MUC5AC ++ + +++ +++ ++++ + 
MUC6 +++ - - + - + 
CDX2 - - + - - - 
CK20 - - - - - - 
CK7 - + + + + + 
KRAS mutation NMD NMD NMD NMD 12CYS (G12C) NMD 
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BRAF mutation NMD NMD NMD NMD NMD NMD 
IDH1/2 mutation NMD NMD NMD NMD NMD NMD 
Survival 
(months) 6 22 0 7 1 * 19 
Status 
Dead (unknown 
cause) 
Alive, 
recurrent 20 
months post-
surgery Dead, sepsis 
Dead 
(unknown 
cause) 
Recurrent 1 
month post-
surgery; 
followup is lost. 
Alive, recurrent 
17 months post-
surgery 
Annotations: NMD, no mutation detected; MD, moderately differentiated; PD, poorly 
differentiated; PSC, primary sclerosing cholangitis; WD, well differentiated. * The followup is lost 
after 1 month. 
If greater than 10% of the tumor cells show cytoplasmic staining (MUC2, MUC5AC, and MUC6) 
or apical membranous or cytoplasmic staining (MUC1), the result is interpreted as positive. The 
result was further scored as 0-4 (0= none – 10% staining, 1= 10-25%, 2= 26-50%, 3= 51-75%, 
and 4= 76-100%). 
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Table 3. Immunohistochemistry of mucinous and conventional intrahepatic 
cholangiocarcinoma (iCC), and liver metastases from known primary of colorectal 
adenocarcinoma. 
 
Immunoreactivity 
Mucinous iCC (n=6) 
Conventional iCC 
(n=12) 
liver metastases 
from colorectal 
primary (n=16) 
MUC1 83% 58% NA 
MUC2 33% 17% NA 
MUC5AC 100% 42% NA 
MUC6 50% 0 NA 
CK7 83% 83% 6% 
CK20 0 17% 94% 
CDX2 17% 0 94% 
PMS2 100% 83% NA 
MSH6 100% 92% NA 
p53 
67% 67% 
NA 
Smad 4 67% 58% NA 
EGFR 83% 42% NA 
Her 2 0 0 NA 
Annotations: NA, not available. 
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Highlight 
 
Mucinous variant of intrahepatic cholangiocarcinoma (iCC) is rare and unique that 
constitutes 7.1% of iCCs. It is more immunoreactive for MUC1, MUC2, MUC5AC and 
MUC6. Unlike mucinous adenocarcinomas of colorectal primary, mucinous iCCs are 
often CK7+/CK20-/CDX2- and microsatellite stable. Patients with mucinous iCC likely 
present at advanced stage upon diagnosis with shorter survival time. 
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